Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3‑yl)phenyl]propan‑1‑ol** is a synthetic small molecule belonging to the isoxazolopyridine class of organic compounds. It has a molecular formula of C23H22ClN3O2 and a molecular weight of approximately 407.9 g/mol. The compound has been cataloged in several chemical and drug databases (e.g., DrugBank DB06897, ChEMBL490814), but there is no evidence it has reached clinical development or approval for any therapeutic indication. Its mechanism of action and biological targets are not described in public sources; it appears to be an experimental or research compound with no known approved medical use[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol.